HGSI Ponders Next Move After Rebuffing GSK's $2.6B Offer
By Marie Powers
Friday, April 20, 2012
As analysts weighed in on the unsolicited offer by GlaxoSmithKline plc (GSK) to purchase Human Genome Sciences Inc. (HGSI) for $13 per share in cash, or $2.6 billion, shares (NASDAQ:HGSI) of the biotech reached $14.61 before closing at $14.17 for a gain of 97.6 percent.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.